Kalaris Therapeutics
KLRS | NASDAQ
$1.46
-$0.11 (-7.30%)
At close: Nov 16, 2026, 4:00 PM ET
$1.46
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-7.30%
(1D)No price chart data available for 1D timeframe.
Rating
34.2
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #679/1021 (Top 67%)
Key Statistics
Market Data
Market Cap $34.76M
1D Range
1.41 1.65
52W Range
1.41 10.98
Valuation (TTM)
PE -0.79
PB 0.73
EV/EBITDA 1.04
Valuation (NTM)
Forward PE N/A
Forward PEG 0.02
Price Target $18.00
Cash Flow
FCF Yield -122.0%
SBC Adj. FCF Yield -124.2%
SBC Impact -1.8%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 64.3% |
63.6%
FCF 3Y | 5Y 5.8% |
37.4%
Returns
ROA -48.8%
ROE -68.8%
ROIC -58.0%
Financial Health
Net Cash
$82.86M
Current Ratio 10.00
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-sta...
Sector Healthcare
Industry Biotechnology
Employees 20
IPO Date Jul 30, 2020
Website kalaristx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
1
Consensus
Buy
Price Target
$18.00
Upside
+1132.88%
Buy (1)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove KLRS